Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR Regulations’), Achyut Healthcare has informed that the Board of Directors of the Company, at its meeting held today July 14, 2026 (Tuesday) at the registered office of the Company, after considering the recommendation of the Audit Committee and the Committee of Independent Directors of the Company, has considered and approved a Scheme of Amalgamation of Achyut Healthcare (‘Transferor Company’) with and into Zenith Healthcare (‘Transferee Company’) and their respective shareholders and creditors (‘Scheme’), under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (‘Act’), rules and regulations made thereunder read with Section 2(6) of the Income Tax Act, 2025, for the aforementioned amalgamation, consequent dissolution of the Transferor Company without winding up and the issuance of equity shares by the Transferee Company to the equity shareholders of the Transferor Company as consideration. The Scheme is subject to requisite approvals and sanction of the appropriate statutory and regulatory authorities including jurisdictional bench of the National Company Law Tribunal (‘NCLT’) and subject to the approval of shareholders and/or creditors. Further, the Scheme shall be filed with BSE for obtaining the no-objection letter/ observation letter in terms of Regulation 37(1) of the SEBI LODR Regulations read with SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023. The details / information as required under Regulation 30 of the SEBI LODR Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, regarding the Scheme are enclosed as ‘Annexure – A’. The aforesaid meeting of the Board of Directors of the Company commenced at 7.05 PM and concluded at 7.50 PM.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Redington | 259.10 |
| Amrapali Industries | 33.31 |
| Adani Enterprises | 3027.15 |
| Rashi Peripheral | 780.30 |
| PDS | 351.85 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: